SCHEMBL359384

SCHEMBL359384

N[C@@H](CS)C(=O)[Fe](C(=O)[C@@H](N)CS)(C(=O)[C@@H](N)CS)C(=O)[C@@H](N)CS

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.55
▸ SLC7A11 Q9UPY5 1/20 0.55
▸ ENPEP Q07075 12/20 0.37
▸ ANPEP P15144 4/20 0.36
▸ MMP2 P08253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1986941 1.00 PTGS1 (0.55) PTGS1SLC7A11ENPEPANPEPMMP2
Cysteine SCHEMBL663461 0.74 — —
Cysteine SCHEMBL663459 0.74 — —
SCHEMBL7878149 0.74 — —
SCHEMBL7878148 0.74 — —
SCHEMBL358881 0.71 — —
Cysteine SCHEMBL5705426 0.71 PTGS1 (1.00) PTGS1SLC7A11ENPEPANPEP
SCHEMBL58409 0.71 — —
Cysteine SCHEMBL21110883 0.71 PTGS1 (1.00) PTGS1SLC7A11ENPEPANPEP
SCHEMBL692227 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366738-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES INC (US) 2024-11-07 — — US disclosed
US-11992518-B2 Molecular vaccines for infectious disease AGILENT TECHNOLOGIES, INC. (US) 2024-05-28 — — US disclosed
EP-3334498-B1 METHODS OF TREATING VOLUME DEPLETION AND KIDNEY INJURY UNIV COLUMBIA (US) 2023-06-07 — — EP disclosed
US-11119104-B2 Methods of treating volume depletion and kidney injury THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-09-14 — — US disclosed
US-10968269-B1 MHC multimers in borrelia diagnostics and disease AGILENT TECHNOLOGIES, INC. (US) 2021-04-06 — — US disclosed
US-20210047383-A1 MHC Multimers in Borrelia Diagnostics and Disease DAKO DENMARK APS (DK) 2021-02-18 — — US disclosed
US-20200347103-A1 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS AGILENT TECHNOLOGIES INC (US) 2020-11-05 — — US disclosed
US-10611818-B2 MHC multimers in tuberculosis diagnostics, vaccine and therapeutics AGILENT TECHNOLOGIES, INC. (US) 2020-04-07 — — US disclosed
US-20190314471-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES, INC. 2019-10-17 — — US disclosed
US-10369204-B2 Molecular vaccines for infectious disease DAKO DENMARK A/S (DK) 2019-08-06 — — US disclosed
WO-2003020897-A2 COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 — — WO disclosed
WO-2003020934-A1 COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 — — WO disclosed
WO-2003020900-A2 COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 — — WO disclosed
WO-2003020901-A2 COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 — — WO disclosed
WO-2003020953-A2 COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 — — WO disclosed
WO-2003020899-A2 COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 — — WO disclosed
US-20020102610-A1 Automated identification of peptides OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2002-08-01 — — US disclosed
US-20020055186-A1 Detection of peptides OXFORD GLYCOSCIENCES (UK) LTD. 2002-05-09 — — US disclosed
WO-2002025287-A2 DETECTION OF PEPTIDES OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2002-03-28 — — WO disclosed
WO-2002021139-A2 AUTOMATED IDENTIFICATION OF PEPTIDES OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2002-03-14 — — WO disclosed
Send feedback